Recorded fact · drug.label_indication

drug.label_indication for vismodegib|basal-cell-carcinoma

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact e2861387 resolves to.

The record

Fact id	`e2861387c7d68337df8b4886`
Entity	drug: vismodegib\|basal-cell-carcinoma
Field	drug.label_indication
Source	api.fda.gov
Read on	2026-11-10T19:02:47.536Z
Source version	openfda-label-20241202
Method	extract
Verification	verified
Licence	CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels
Edition	2026-11, Merkle root `006ab9a329709cbe...`

The verifying quote

ERIVEDGE is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation.

Shown with dashes as hyphens. SHA-256 of the exact stored quote: 4f1ff74ccac6155c72b9ed621fa6370518793986326e6740ce9bf75c16c1a5a4.

The value

{
 "ingredient": "Vismodegib",
 "conditionId": "basal-cell-carcinoma",
 "conditionName": "Basal cell carcinoma",
 "matchedAlias": "basal cell carcinoma",
 "context": "indication",
 "brand": "ERIVEDGE",
 "identifiedVia": "generic_name",
 "extractor": 5,
 "labelSetId": "eb368bb6-80e3-4df9-8a85-91df0a2ada6a",
 "labelEffectiveTime": "20241202",
 "labelsRead": 1,
 "labelsNaming": 1,
 "registryEditionRoot": "1b44e76f5da1a417",
 "meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}

SHA-256 of the exact stored value: 1b3bfc0caa79a66dee1e1a549bd5dfc40f6ebfffca0c626a3fbd370e31f60168.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.